ARS clinical development team submitted several clinical trial applications (CTAs) to the Russian Ministry of Health (MoH) last January and February. These will be local single-site randomized cross-over comparison studies of pharmacokinetics and bioequivalence (PK/BE) of tableted generics like Pantoprazole, Darunavir, Telmisartan, Gefitinib, Bosentan, Albendazole, Rosuvastatin, Abiraterone, Tenofovir, and Pazopanib performed for seven Indian Sponsors for their drugs’ marketing authorization in Russia.